FDA approves first twice-yearly injection that prevents HIV infection

The U S Food and Drug Administration FDA approved a new twice-yearly shot the first and only of its kind to prevent HIV the creator of the drug Gilead Sciences reported on Wednesday Sold under the name Yeztugo the company s injectable HIV- capsid inhibitor lenacapavir reduces the liability of sexually acquired HIV in adults and adolescents This is a historic day in the decades-long fight against HIV announced Daniel O Day chairman and CEO of California-based Gilead Sciences in a press release ALZHEIMER'S SICKNESS COULD BE PREVENTED BY ANTIVIRAL DRUG ALREADY ON MARKETThe medicine which only demands to be administered twice a year has shown remarkable outcomes in clinical studies as Gilead insists it could transform HIV prevention The drug is given as an injectable under the skin that the body then slowly absorbs Individuals must have a negative HIV- test prior to starting the cure In large trials last year the drug was not only nearly effective in its prevention of HIV but proved superior to once-daily oral medication like Truvada another drug by Gilead The journal Science named lenacapavir its Breakthrough of the Year CLICK HERE TO SIGN UP FOR OUR FITNESS NEWSLETTERLenacapavir uses a multi-stage approach that distinguishes it from other approved antiviral medications While largest part antivirals act on just one stage of viral replication lenacapavir is designed to inhibit HIV at multiple stages of its lifecycle states the press release from Gilead For more Wellness articles visit www foxnews com physical condition Yeztugo is one of the majority of central scientific breakthroughs of our time and offers a very real opportunity to help end the HIV epidemic O Day revealed in the press release The the greater part commonly communicated adverse reactions during clinical trials included injection site reactions headache and nausea according to the company